Insulet has completed two asset purchases that should about double the Massachusetts-based company’s portfolio of pump and automated insulin delivery (AID) technologies.

The developer of the Omnipod tubeless automated insulin delivery system has paid $25 million to Bigfoot Biomedical, a Milpitas, Calif.-based developer of intelligent connected injection support systems, for its pump-based AID technologies, including patents for pumps that may be used for AID therapy.

Insulet has also acquired the assets of Palo Alto, Calif.-based Automated Glucose Control (AGC), a company focused on developing and commercializing AID technologies, for $25 million. The acquisition includes patents and other intellectual property that AGC had licensed from the University of California in Santa Barbara as part of a 2016 partnership.

“It is exciting to see technology come out of the research lab and mature into a commercial application that improves the lives of people with diabetes,” said Eric Benjamin, Insulet’s executive vice president of innovation, strategy, and digital products.